Navigation Links
AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer

ht; position: relative;">

"AV-412 showed potent inhibition of the EGFR L858R mutations and, in two well-established animal models, demonstrated dose-dependant tumor regression in both small and large lung tumors and complete regression of lung tumors at a dose where erlotinib is inactive," said Tuan Ha-Ngoc, President and CEO of AVEO Pharmaceuticals. "These data, while early, highlight the promise of AV-412 as an option for lung cancer patients who carry the EGFR L858R mutation, as well as patients who become resistant to first-generation tyrosine kinase inhibitors. We are looking forward to initiating Phase 2 trials as soon as we establish an appropriate dose in the current Phase 1 study, which was initiated last October."

To provide robust models for translational research supporting the development of novel agents for lung cancer, AVEO generated a series of inducible mouse lung cancer models using AVEO's Human Response Prediction(TM) Platform. Using this proprietary platform, AVEO generated several different models covering the most prevalent oncogenic mutations including EGFR(L858R), EGFR(L858R/T790M) and KRAS(G12V). Unlike studies in primary genetically engineered tumor models, this approach enables the quantitative and comparative analysis of different drugs, doses, schedules and combinations to optimize drug selection and clinical trial design in the clinic.

Utilizing these novel models, AVEO evaluated the activity of AV-412 in non-small cell lung cancer tumors. Data presented today at the AACR meeting show that AV-412 is highly active against tumors from the chimeric model carrying the EGFRL858R mutation, exhibiting an ED50 of 0.1 mg/kg as a daily dose. AV-412 is greater than 10 times more potent than erlotinib in this model, one mg/kg PO AV-412 resulted in complete tumor regression, whereas erlotinib is active at 10mg/kg, but inactive at 1mg/kg. More importantly, AV-412 was found to be active against tumors from chimeric lung adenocar
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:3/27/2015)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: ... issuance of an aggregate of 30,000 stock options to ... of 120,500 stock options to employees and consultants of ... years and will be exercisable for a period of ... stock option. About Covalon Covalon Technologies ...
(Date:3/27/2015)... - Medicure Inc. (the "Company") (TSXV:MPH, OTCQB:MCUJF) announces today ... of an aggregate of 236,070 options to certain directors, ... Company pursuant to the Company,s Stock Option Plan. Of ... tenth anniversary of the date of grant, 5,000 are ... date of grant and 50,000 are set to expire ...
(Date:3/27/2015)... , March 27, 2015  Holographic Optical Technologies of ... field of holographic medical imaging, is entering the world ... campaign. Launching on April 20 th , 2015, the ... Pro. The 8-inch and 22-inch displays will allow consumers ... the first time. In addition to the two displays, ...
Breaking Medicine Technology:Covalon Announces Issuance of Stock Options 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3
... 28, 2011 Shire plc , (LSE: SHP, Nasdaq: ... announced that the US Food and Drug Administration (FDA) approved ... as adjunctive therapy to stimulants for the treatment of attention ... to 17 as part of a total treatment program. The ...
... Feb. 28, 2011 Sangamo BioSciences, Inc. (Nasdaq: ... preliminary clinical data from its Phase 1 trial (SB-728-902). ... subjects who are currently on highly active antiretroviral therapy ... CD4+ T-cell counts.  The study is designed to evaluate ...
Cached Medicine Technology:FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 2FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 3FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 4FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 5FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 6Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 2Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 3Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 4Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 5Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 6
(Date:3/28/2015)... California (PRWEB) March 28, 2015 Designers ... a new overlay entitled Scratches 5K from Pixel Film ... scratch effects to any media inside Final Cut Pro ... “StoryBoard Corporate saves time and is an effective tool ... using FCPX Overlay Scratches 5K's intuitive grunge overlays. Simply ...
(Date:3/27/2015)... The Monogamy Method - ... Sanderson and Jason Rogers has just been released to ... The commotion surrounding the course's launch has caught the ... an in-depth review of the new program. , "Many ... their lives suddenly start pulling away or expressing interest ...
(Date:3/27/2015)... First Choice Emergency Room opened ... is located 12665 W Lake Houston Pkwy, Houston, Texas and ... I look forward to delivering the highest quality emergency medical ... Director of First Choice Emergency Room Summerwood. , ... donation to Summer Creek High School at First Choice Emergency ...
(Date:3/27/2015)... March 27, 2015 Ticket Down is a reputable ... in 2015. After a phenomenal and highly successful live tour ... be going out on tour again in 2015 and they will ... underway on April 29th in New York City at the cozy ... Comerica Theatre on May 10th. , Fans of the hit show ...
(Date:3/27/2015)... KING OF PRUSSIA, PA and LONDON, UK (PRWEB) March ... and current President of DrugDev SiteStart Melissa (Liss) Easy ... Under 40. , The 40 Under 40 list ... of age for their professional accomplishments and community involvement. ... and profiled in a special supplement of the Philadelphia ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:First Choice Emergency Room Opens New Facility in Houston, Texas 2Health News:Nashville Live in Concert Tickets in New York, Boston, Washington, DC, Chicago, Minneapolis, San Francisco, Los Angeles and Phoenix Now On Sale at TicketDown.com 2Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2
... Britain, women admitted in hospital wards are facing inconvenience and ... to rest comfortably as they fear sexual assault. ... have been calling them complaining of inconvenience and invasion of ... instance, a woman in her 70s was totally upset and ...
... made this summer when the U.S. Food and Drug ... cancer//. The vaccine was given the green light for ... against human papillomavirus (HPV), a sexually transmitted virus that ... for a cancer ever developed,” said Phyllis Greenberger, president ...
... that hospitals need to spruce up with infrastructure that ... //patients requiring emergency care. There appears to be immense ... be addressed without delay. , ,Dr Peter Grant, ... "Emergency departments and primary care providers must prepare for ...
... government has issued a directive to the provincial livestock authorities ... //to prevent potential bird flu that had left an indelible ... ,Yukol Limlamthong, the person at the helm at the Department ... up following the recent deluge in the central provinces. Thailand ...
... that majority of Australians actually know very little about lymphomas. ... is termed as lymphomas. Its the lymphatic system in the ... aids to fight disease. ,Data reveals that it’s ... cervical or ovarian cancer .Survey shows that more Australians die ...
... by researchers from the Royal Devon and Exeter Hospital postulates ... born short. //Mothers seem to determine how plump babies finally ... the researchers say that results derived so far, clearly point ... of fat fathers, however, did not seem to be on ...
Cached Medicine News:Health News:Triumphs and Hurdles for the New HPV Vaccine 2Health News:Triumphs and Hurdles for the New HPV Vaccine 3
Designed by a neonatalogist to reduce the number of steps required to suction meconium from the infants trachea when seconds count. Meconium suction system optimizes patient and provider safety....
... KIMBERLY-CLARK BALLARD Neonatal ... Elbow is designed for ... of elbow design provide ... lavage/irrigation port and locking ...
KIMBERLY-CLARK BALLARD Neonatal and Pediatric TRACH CARE Y features lavage/irrigation port and locking thumb port. Multiple French sizes and packaging configurations. Gamma sterilized....
... PVC siliconized. Stainless steel spiral reinforced. X-ray opaque ... use. Adjustable Flange: The flange can be adjusted ... of the cervical soft tissue. The lock ring ... connected to the shaft. Maximum Patient Comfort: The ...
Medicine Products: